• Please log in or register to access this feature.
You have full text access to this OnlineOpen article

CDP571, a humanized monoclonal antibody to tumour necrosis factor-α, for steroid-dependent Crohn's disease: a randomized, double-blind, placebo-controlled trial

  1. B. G. FEAGAN1,
  2. W. J. SANDBORN2,
  3. G. LICHTENSTEIN3,
  4. G. RADFORD-SMITH4,
  5. J. PATEL5,
  6. A. INNES5

Article first published online: 14 FEB 2006

DOI: 10.1111/j.1365-2036.2006.02791.x

Issue

Alimentary Pharmacology & Therapeutics

Alimentary Pharmacology & Therapeutics

Volume 23, Issue 5, pages 617–628, March 2006

Additional Information

How to Cite

FEAGAN, B. G., SANDBORN, W. J., LICHTENSTEIN, G., RADFORD-SMITH, G., PATEL, J. and INNES, A. (2006), CDP571, a humanized monoclonal antibody to tumour necrosis factor-α, for steroid-dependent Crohn's disease: a randomized, double-blind, placebo-controlled trial. Alimentary Pharmacology & Therapeutics, 23: 617–628. doi: 10.1111/j.1365-2036.2006.02791.x

Author Information

  1. 1

    University of Western Ontario, London, ON, Canada

  2. 2

    Mayo Clinic, Rochester, MN, USA

  3. 3

    University of Pennsylvania, Philadelphia, PA, USA

  4. 4

    Royal Brisbane Hospital, Herston, Qld, Australia

  5. 5

    UCB Pharma Limited, Slough, UK

*Dr B. G. Feagan, Robarts Research Institute, University of Western Ontario, Robarts Clinical Trials, 100 Perth Drive, London, ON, Canada N6A 5K8. E-mail: bfeagan@robarts.ca

Publication History

  1. Issue published online: 14 FEB 2006
  2. Article first published online: 14 FEB 2006
  3. Publication data Submitted 26 July 2005 First decision 29 July 2005 Resubmitted 8 December 2005 Accepted 8 December 2005

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (3652K)

References

  • 1
    Summers RW, Switz DM, Sessions JT Jr, et al. National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology 1979; 77: 847–69.
  • 2
    Faubion WJ, Loftus EJ, Harmsen WS, et al. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 2001; 121: 255–60.
  • 3
    Candy S, Wright J, Gerber M, et al. A controlled double blind study of azathioprine in the management of Crohn's disease. Gut 1995; 37: 674–8.
  • 4
    Markowitz J, Grancher K, Kohn N, et al. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease. Gastroenterology 2000; 119: 895–902.
  • 5
    Feagan BG, Rochon J, Fedorak RN, et al. Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators. N Engl J Med 1995; 332: 292–7.
  • 6
    Feagan BG, Fedorak RN, Irvine EJ, et al. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators. N Engl J Med 2000; 342: 1627–32.
  • 7
    Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997; 337: 1029–35.
  • 8
    Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359: 1541–9.
  • 9
    Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003; 348: 601–8.
  • 10
    Farrell RJ, Alsahli M, Jeen YT, et al. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial. Gastroenterology 2003; 124: 917–24.
  • 11
    Hanauer SB, Wagner CL, Bala M, et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol 2004; 2: 542–53.
  • 12
    Winter G, Harris WJ. Humanized antibodies. Immunol Today 1993; 14: 243–6.
  • 13
    Stephens S, Emtage S, Vetterlein O, et al. Comprehensive pharmacokinetics of a humanized antibody and analysis of residual anti-idiotypic responses. Immunology 1995; 85: 668–74.
  • 14
    Stack WA, Mann SD, Roy AJ, et al. Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn's disease. Lancet 1997; 349: 521–4.
  • 15
    Sandborn WJ, Feagan BG, Hanauer SB, et al. An engineered human antibody to TNF (CDP571) for active Crohn's disease: a randomized double-blind placebo-controlled trial. Gastroenterology 2001; 120: 1330–8.
  • 16
    Feagan BG, Sandborn WJ, Baker JP, et al. A randomized, double-blind, placebo-controlled trial of CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, in patients with corticosteroid-dependent Crohn's disease. Aliment Pharmacol Ther 2005; 21: 373–84.
    Direct Link:
  • 17
    Best WR, Becktel JM, Singleton JW, et al. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology 1976; 70: 439–44.
  • 18
    Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999; 340: 1398–405.
  • 19
    Irvine EJ, Feagan B, Rochon J, et al. Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn's Relapse Prevention Trial Study Group. Gastroenterology 1994; 106: 287–96.
  • 20
    Irvine EJ, Feagan BG, Wong CJ. Does self-administration of a quality of life index for inflammatory bowel disease change the results? J Clin Epidemiol 1996; 49: 1177–85.
  • 21
    Sandborn WJ, Feagan BG, Radford-Smith G, et al. CDP571, a humanised monoclonal antibody to tumour necrosis factor alpha, for moderate to severe Crohn's disease: a randomised, double-blind, placebo-controlled trial. Gut 2004; 53: 1485–493.
  • 22
    Hanauer S, Present D, Targan SR, et al. CDP571, a humanized monoclonal antibody to TNF-α, is well tolerated in Crohn's disease patients with previous hypersensitivity to infliximab. Gastroenterology 2003; 124: A-517.
View Full Article (HTML) Get PDF (3652K)